The effectiveness of sildenafil citrate in patients with erectile dysfunction and lower urinary system symptoms and the significance of asymptomatic inflammatory prostatitis

International Journal of Impotence Research

Volumn 22, Issue 6, 2010, Pages 349-354

  Eryildirim, B ^a   Aktas, A ^a   Kuyumcuoglu, U ^a   Faydaci, G ^a   Tarhan, F ^a   Ozgul A ^a  

^a DR LUTFI KIRDAR KARTAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

asymptomatic inflammatory prostatitis; erectile dysfunction; lower urinary tract symptoms; questionary; sildenafil citrate

Indexed keywords

SILDENAFIL;

ADULT; ARTICLE; CALCULATION; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MALE; NATIONAL HEALTH INSTITUTE CHRONIC PROSTATITIS SYMPTOM INDEX; PARAMETER; PRIORITY JOURNAL; PROSTATITIS; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SYMPTOM;

AGED; ERECTILE DYSFUNCTION; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROSTATITIS; PURINES; QUALITY OF LIFE; SULFONES; TREATMENT OUTCOME; UROLOGIC DISEASES;

EID: 78650622381     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2010.26     Document Type: Article

References (26)

1. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-649.
2. Costabile RA, Steers WD. How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006; 3: 676-681.
3. Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 2010; 20: 49-54.
4. Carson CC. Combination of phosphodiesterase-5 inhibitors and alfa-blockers in patients with benign prostatic hyperplasia: Treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 2006; 97: 39-43.
5. Marszalek M, Wehrberger C, Hochreiter W, Temml C, Madersbacher S. Symptoms suggestive of chronic pelvic pain syndrome in an urban population: Prevalence and associations with lower urinary tract symptoms and erectile function. J Urol 2007; 177: 1815-1819.
6. Müller A, Mulhall JP. Sexual dysfunction in the patient with prostatitis. Curr Opin Urol 2005; 15: 404-409.
7. Liang CZ, Zhang XJ, Hao ZY, Shi HQ, Wang KX. Prevalence of sexual dysfunction in Chinese men with chronic prostatitis. BJU Int 2004; 93: 568-570.
8. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009; 36: 403-415.
9. Krieger JN, Nyberg Jr L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 282: 236-237.
10. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al. The American Urological Association Symptom Index for benign prostatic hyperplasia.The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-1557.
11. Litwin MS, McNaughton-Collins M, Fowler Jr. FJ, Nickel JC, Calhoun EA, Pontari MA et al. The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999; 162: 369-375.
12. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-326.
13. McVary K. Lower urinary tract symptoms and sexual dysfunction: Epidemiology and pathophysiology. BJU Int 2006; 97: 23-28. (Pubitemid 43356992)
14. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: Results from the BPH registry. Urology 2009; 73: 562-566.
15. Ying J, Yao D, Jiang Y, Ren X, Xu M. The positive effect of sildenafil on LUTS from BPH while treating ED. Zhonghua Nan Ke Xue 2004; 10: 681-683.
16. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study. J Urol 2008; 180: 1228-1234.
17. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53: 1236-1244.
18. Liang CZ, Zhang XJ, Hao ZY, Shi HQ, Wang KX. Prevalence of sexual dysfunction in Chinese men with chronic prostatitis. BJU Int 2004; 93: 568-570.
19. Tuncel A, Akbulut Z, Atan A, Basar MM. Common symptoms in men with prostatic inflammation. Int Urol Nephrol 2006; 38: 583-586.
20. Turner JA, Hauge S, Von Korff M, Saunders K, Lowe M, Berger R. Primary care and urology patients with the male pelvic pain syndrome: Symptoms and quality of life. J Urol 2002; 167: 1768-1773.
21. Aubin S, Berger RE, Heiman JR, Ciol MA. The association between sexual function, pain, and psychological adaptation of men diagnosed with chronic pelvic pain syndrome type III. J Sex Med 2008; 5: 657-667.
22. Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F et al. Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis. Prostate 2009; 69: 1774-1780.
23. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25-29.
24. Ozden C, Ozdal OL, Guzel O, Han O, Seckin S, Memis A. The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. Int Urol Nephrol 2007; 39: 859-863.
25. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE trial. Eur Urol 2008; 54: 1379-1384.
26. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78: 539-552.